10x Genomics, Inc. — Director's Dealing 2020

Oct 5, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2020-10-01

Reporting Person: Saxonov Serge (Director, Chief Executive Officer, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-10-01	Class A Common Stock	M	6250	$1.20	Acquired	973431	Direct
2020-10-01	Class A Common Stock	M	3750	$5.04	Acquired	977181	Direct
2020-10-01	Class A Common Stock	S	1600	$124.345	Disposed	975581	Direct
2020-10-01	Class A Common Stock	S	6150	$125.5439	Disposed	969431	Direct
2020-10-01	Class A Common Stock	S	2250	$126.0774	Disposed	967181	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-10-01	Stock Option (right to buy)	$1.20	M	6250	Disposed	2027-10-18	Class A Common Stock (6250)	Direct
2020-10-01	Stock Option (right to buy)	$5.04	M	3750	Disposed	2028-11-02	Class A Common Stock (3750)	Direct

Footnotes

F1: This option exercise was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2: This sale was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F3: This transaction was executed in multiple trades at prices ranging from $123.86 to $124.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F4: This transaction was executed in multiple trades at prices ranging from $124.91 to $125.87. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F5: This transaction was executed in multiple trades at prices ranging from $125.91 to $126.88. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F6: This option, originally for 300,000 shares, of which 177,640 have been exercised, vested as to one-forty-eighth of the shares on October 1, 2017, and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

F7: This option, originally for 250,000 shares, of which 117,985 have been exercised, vested as to one forty-eighth of the shares on October 1, 2018, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.